Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...

Investment losses are painful at any point, but losing stocks are even harder to stomach when the market is in the midst of a ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Biogen Inc. (NASDAQ:BIIB) shares tumbled to a 52-week low of $139.7, reflecting a stark downturn in the biotechnology firm's market performance. With a market capitalization of $20.38 billion and a ...

In the fourth quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...

While the strategic review process is underway, Sage Therapeutics continues to advance its mission of pioneering solutions to deliver life-changing brain health medicines. The company is committed to ...